HMGB1 facilitates PDGF-B production and angiogenesis in rheumatoid arthritis through RAF, MEK and ERK signaling
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115227 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Trung-Loc Ho und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: HMGB1 Protein, Arthritis, Rheumatoid, Neovascularization, Pathologic, Proto-Oncogene Proteins c-sis. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Science and Technology Council, China Medical University.
Abstract (Originalsprache)
Chronic systemic inflammation and autoimmunity are hallmarks of rheumatoid arthritis (RA), an inflammatory illness that gradually deteriorates the joints and results in permanent disability. An important pathogenic mechanism in RA is angiogenesis, which draws inflammatory leukocytes into the synovium and encourages the synthesis of damaging proteases and proinflammatory cytokines. High-mobility group box-1 (HMGB1) is a common nuclear protein with extracellular inflammatory ability that plays a crucial function in inflammatory disorders. Using data from the GEO dataset, the present report determined that the expression levels of HMGB1, the vascular marker CD34, and the angiogenic factor PDGF-B were remarkably higher in RA patients than in normal controls. HMGB1 treatment enhanced PDGF-B production in RA synovial fibroblasts (RASFs), while a PDGF-B antibody blocked HMGB1-treated RASFs-induced angiogenesis in HUVECs. We also revealed that the RAF, MEK, and ERK signaling pathways mediate HMGB1-induced PDGF-B production and angiogenesis. Thus, the HMGB1/PDGF-B axis may serve as a novel target for RA treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
- Division of Immunology and Rheumatology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; School of Medicine, China Medical University, Taichung, Taiwan.
- School of Medicine, China Medical University, Taichung, Taiwan.
- Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan.
- Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan; Department of Sports Medicine, College of Health Care, China Medical University, Taichung, Taiwan.
Förderung
- National Science and Technology Council
- China Medical University
Zitieren
APA
Ho, T. L., Huang, C. C., Chang, C. L., Huang, Y. J., Wang, Y. J., He, X. Y., Ko, C. Y., Chen, H. T., Su, C. M., & Tang, C. H. (2025). HMGB1 facilitates PDGF-B production and angiogenesis in rheumatoid arthritis through RAF, MEK and ERK signaling. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115227
Vancouver
Ho TL, Huang CC, Chang CL, Huang YJ, Wang YJ, He XY, et al. HMGB1 facilitates PDGF-B production and angiogenesis in rheumatoid arthritis through RAF, MEK and ERK signaling. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115227
BibTeX
@article{Ho2025,
author = {Ho, Trung-Loc and Huang, Chien-Chung and Chang, Chin-Lun and Huang, Yun-Jie and Wang, Yu-Jen and He, Xiu-Yuan and Ko, Chih-Yuan and Chen, Hsien-Te and Su, Chen-Ming and Tang, Chih-Hsin},
title = {HMGB1 facilitates PDGF-B production and angiogenesis in rheumatoid arthritis through RAF, MEK and ERK signaling},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115227}
}
EUVIMED